Launching https://t.co/XPqbIcgSFT today = 5 years of hard work!
A free, oncologist-curated heme/onc resource — built for the bedside, the boards, and everyone in between.
Every entry cross-checked against OpenEvidence
@EvidenceOpen = Zero errors flagged.
What's inside ↓
📢Applicants! Here’s how to look at which programs are participating in the Voluntary Rank Order List Lock pilot and have certified and locked their Rank Order List (ROL): https://t.co/cmwvlQCTwv
#Match2026#NRMP
@JoshuaOommen2 Loved the discussion on physician disputes. Never knew it could be put into words like that. And for D-dimer, as you've rightly said, "Clinical context is key!"
1/
Why can furosemide improve dyspnea/pulmonary edema from acute congestive heart failure within minutes of administration?
The answer does not involve diuresis.
#medtwitter#tweetorial
🚨Now Online in Reviews in Cardiovascular Medicine!
🫀Spotlight on Coronary Artery Dissection
✍️Authors: Aro Daniela Arockiam, Praveen Bharath Saravanan, Priyansha Singh, Aonghus J. Feeney, @AnkitAgrawalMD
📖Read it here: https://t.co/iHDGPyKxdL
#CoronaryArteryDissection
I just found out we don't use the suffix 'mab' for new monoclonal antibodies anymore — now it's -tug/-bart/-mig/-ment
So, for the new amyloid antibody, Remternetug
'Remter–' is a random prefix; '–ne' is for neurology and '–tug' because it's unmodified and monospecific